CTLA4
ENSG00000163599
Target class
Surface antigen
Chromosome
2
Approved drugs
2
Clinical candidates (approved and in development)
6
- Approved drugs
- 2
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- CTLA4
- Gene name
- Cytotoxic T-lymphocyte associated protein 4
- Gene symbol
- CTLA4
- Protein name
- Cytotoxic T-lymphocyte protein 4 (Cytotoxic T-lymphocyte-associated antigen 4) (CTLA-4) (CD antigen CD152)
- CD152
- CD
- GSE
- CTLA-4
- CELIAC3
- IDDM12
- Gene biotype
- Protein coding
- Gene family
- CD molecules|V-set domain containing
- Target class
- Surface antigen
- Target type
- Human gene
- Tissues expressed in
- 10
- Highest tissue expression
- 5.8
- Tissue specificity (Gini)
- 0.621
- Tissue specificity (tau)
- 0.892
- KEGG gene identifiers
- hsa:1493
- Protein interaction confidence
- 0.837743
- Protein interaction partners
- 105
- R-HSA-389356
- R-HSA-389513
- R-HSA-8877330
- End position
- 203873965
- Start position
- 203853888
- Chromosome
- 2
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Note=Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalization. .
- PubMed 18468488
- PubMed 18641304
- PubMed 28484017
- Tissue specificity (tau)
- 0.891574
- Expression inequality (Gini)
- 0.620993
Expression in transcripts per million
- Spleen
- 5.8
- Small Intestine - Terminal Ileum
- 4.93
- Lung
- 4.35
- Testis
- 2.53
- Whole Blood
- 1.78
Expression in transcripts per million
- Spleen5.8
- Small Intestine - Terminal Ileum4.93
- Lung4.35
- Testis2.53
- Whole Blood1.78
- Fallopian Tube1.22
- Adipose - Visceral (Omentum)1.05
- Colon - Transverse1.04
- Esophagus - Mucosa1.03
- Vagina1.01
- Breast - Mammary Tissue0.82
- Artery - Coronary0.77
- Prostate0.76
- Thyroid0.76
- Cervix - Endocervix0.74
- Kidney - Medulla0.73
- Skin - Not Sun Exposed (Suprapubic)0.71
- Nerve - Tibial0.68
- Artery - Aorta0.64
- Adipose - Subcutaneous0.63
- Bladder0.58
- Cervix - Ectocervix0.57
- Stomach0.53
- Minor Salivary Gland0.52
- Skin - Sun Exposed (Lower leg)0.39
And 29 more, listed on the interactive page.
- GO:0006955
- GO:0006974
- GO:0030889
- GO:0043065
- GO:0045590
- GO:0050853
- GO:0050860
- GO:0050868
- GO:0005794
- GO:0005886
- GO:0009897
- GO:0045334
- GO:0048471
- GO:0098636
- GO:0005515
- GO:0140319
Related records
Trials (1,350)
- ......SMARTEST Trial......
- A 2-part Phase 1/2 Open-label Trial on ODM-212
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
- A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
- A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
- A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
- A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
- A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
- A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
- A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
- A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
- A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
- A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)
- A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
- A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
Drugs (6)
- Cadonilimab Cytotoxic T-lymphocyte protein 4 inhibitor
- Erfonrilimab Cytotoxic T-lymphocyte protein 4 inhibitor
- Ipilimumab Cytotoxic T-lymphocyte protein 4 inhibitor
- Quavonlimab Cytotoxic T-lymphocyte protein 4 inhibitor
- Tremelimumab Cytotoxic T-lymphocyte protein 4 inhibitor
- Zalifrelimab Cytotoxic T-lymphocyte protein 4 inhibitor